{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:21:45Z","timestamp":1783171305736,"version":"3.54.6"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vellore Institute of Technology (VIT) Seed","award":["Grant Year 2020\/2021"],"award-info":[{"award-number":["Grant Year 2020\/2021"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Breast cancer remains the leading cause of cancer-related deaths in women. Therefore, developing targeted combination therapies that improve overall survival in breast cancer patients continues to pose a major clinical challenge. Etoposide (ETO), a topoisomerase II inhibitor that induces transient double-strand breaks by blocking the cleavable complex, is currently used in high doses to treat radioresistant or metastatic breast cancers. To enhance the effectiveness of radiation and chemotherapy, targeting molecular mechanisms involved in DNA repair of induced DNA lesions could selectively increase tumor cell death. Since the effects of ETO are primarily seen during the S\/G2 phases of the cell cycle, its efficacy could potentially be enhanced by using an inhibitor of a DNA repair gene involved in homologous recombination, which is mainly active during these phases. In this context, synthetic lethality refers to the concept that inhibiting or mutating two or more genes simultaneously leads to greater cell death than altering them individually. The FDA approval of Olaparib, a specific PARP inhibitor for BRCA-mutated breast cancer patients, has motivated researchers to explore other synthetic lethal interactions that could increase DNA damage accumulation, leading to cancer cell death. We demonstrate that successive treatment of breast cancer cells with specific inhibitors of ATM kinase and topoisomerase II\n                    <jats:italic>in vitro<\/jats:italic>\n                    can induce increased apoptosis. ATM is an apical kinase that recognizes DNA double-strand breaks and activates the homologous recombination repair pathway, either directly or through cell cycle checkpoint control. Topoisomerase II poisons generate enzyme-mediated DNA damage, leading to permanent double-strand breaks. Cytokinesis-block micronucleus assay was performed to assess the increase in DNA damage during combination treatment with inhibitors. Additionally, cell viability tests and fluorescent staining assay were conducted to evaluate the extent of cell death. We found that targeting ETO-treated breast cancer cells with an ATM kinase inhibitor, KU-55933 (KU) induced higher chromosomal damage\/aberrations, as evaluated by the cytokinesis-block micronucleus assay. The ATM kinase inhibitor also significantly reduced the viability of ETO-treated breast cancer cells.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0340472","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:29:26Z","timestamp":1768933766000},"page":"e0340472","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-4528","authenticated-orcid":true,"given":"Arun R. K.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal Sara","family":"Shaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aswathi","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombodhi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilner","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8862-9660","authenticated-orcid":true,"given":"Radha","family":"Saraswathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"3","key":"pone.0340472.ref001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"pone.0340472.ref002","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: Evolution of the treatment paradigm","volume":"86","author":"AM Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"pone.0340472.ref003","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","article-title":"Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors?","volume":"15","author":"A Ashworth","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6330","key":"pone.0340472.ref004","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"CJ Lord","year":"2017","journal-title":"Science"},{"issue":"10","key":"pone.0340472.ref005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"NJ O\u2019Neil","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"10","key":"pone.0340472.ref006","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.trecan.2018.08.003","article-title":"Synthetic lethality and cancer - Penetrance as the major barrier","volume":"4","author":"CJ Ryan","year":"2018","journal-title":"Trends Cancer"},{"issue":"9","key":"pone.0340472.ref007","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"WG Jr Kaelin","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"pone.0340472.ref008","first-page":"95","article-title":"Molecular mechanisms of etoposide","volume":"14","author":"A Montecucco","year":"2015","journal-title":"EXCLI J"},{"issue":"6","key":"pone.0340472.ref009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"JC Wang","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"pone.0340472.ref010","first-page":"342","volume-title":"Cancer chemotherapy and biotherapy principles and practice","author":"A Sparreboom","year":"2010"},{"key":"pone.0340472.ref011","first-page":"381","article-title":"Topoisomerase interactive agents.","volume-title":"Cancer Principles and Practice of Oncology","author":"CH. Takimoto","year":"2005"},{"key":"pone.0340472.ref012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","article-title":"New mechanistic and functional insights into DNA topoisomerases","volume":"82","author":"SH Chen","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"pone.0340472.ref013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BCJ20160583","article-title":"Topoisomerases as anticancer targets","volume":"475","author":"JL Delgado","year":"2018","journal-title":"Biochemical Journal"},{"issue":"18","key":"pone.0340472.ref014","first-page":"5077","article-title":"Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin","volume":"49","author":"YH Hsiang","year":"1989","journal-title":"Cancer Res"},{"key":"pone.0340472.ref015","article-title":"Topoisomerase II Inhibitors: The Epipodophyllotoxins, Acridines, and Ellipticines.","volume-title":"Cancer Chemotherapy & Biotherapy: Principles and Practice","author":"YG. Pommier","year":"2006","edition":"4"},{"issue":"6041","key":"pone.0340472.ref016","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1204117","article-title":"Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide","volume":"333","author":"C-C Wu","year":"2011","journal-title":"Science"},{"issue":"28","key":"pone.0340472.ref017","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1021\/bi700272u","article-title":"Topoisomerase II\u2212drug interaction domains: identification of substituents on etoposide that interact with the enzyme","volume":"46","author":"AM Wilstermann","year":"2007","journal-title":"Biochemistry"},{"issue":"7","key":"pone.0340472.ref018","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1091\/mbc.12.7.2109","article-title":"Etoposide induces the dispersal of DNA ligase I from replication factories","volume":"12","author":"A Montecucco","year":"2001","journal-title":"Mol Biol Cell"},{"issue":"1","key":"pone.0340472.ref019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/cr.2007.111","article-title":"Regulation of DNA double-strand break repair pathway choice","volume":"18","author":"M Shrivastav","year":"2008","journal-title":"Cell Res"},{"key":"pone.0340472.ref020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2199-8-29","article-title":"Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition","volume":"8","author":"R Aguilar-Quesada","year":"2007","journal-title":"BMC Mol Biol"},{"issue":"6","key":"pone.0340472.ref021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/emmm.201200229","article-title":"Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53","volume":"4","author":"CT Williamson","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"13","key":"pone.0340472.ref022","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","volume":"13","author":"E Kubota","year":"2014","journal-title":"Cell Cycle"},{"key":"pone.0340472.ref023","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"AM Weber","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"4","key":"pone.0340472.ref024","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10334-013-0420-5","article-title":"A preliminary study on the effects of acute ethanol ingestion on default mode network and temporal fractal properties of the brain","volume":"27","author":"AM Weber","year":"2014","journal-title":"MAGMA"},{"issue":"23","key":"pone.0340472.ref025","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1200\/JCO.2005.05.4171","article-title":"DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes","volume":"24","author":"RD Kennedy","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0340472.ref026","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1172\/JCI31245","article-title":"Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated","volume":"117","author":"RD Kennedy","year":"2007","journal-title":"J Clin Invest"},{"key":"pone.0340472.ref027","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/B978-0-12-396521-9.00008-5","article-title":"Inhibition of DNA repair as a therapeutic target","volume-title":"Cancer Drug Design and Discovery","author":"S Veuger","year":"2014"},{"issue":"2","key":"pone.0340472.ref028","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"AR Venkitaraman","year":"2002","journal-title":"Cell"},{"issue":"2","key":"pone.0340472.ref029","first-page":"227","article-title":"Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models","volume":"381","author":"B Kaina","year":"1997","journal-title":"Mutat Res"},{"issue":"17","key":"pone.0340472.ref030","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1093\/emboj\/20.17.4704","article-title":"Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences","volume":"20","author":"A Tutt","year":"2001","journal-title":"EMBO J"},{"issue":"7","key":"pone.0340472.ref031","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/hmg\/ddp033","article-title":"Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients","volume":"18","author":"JM Flanagan","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"24","key":"pone.0340472.ref032","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1038\/sj.onc.1205485","article-title":"Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line","volume":"21","author":"W Kim","year":"2002","journal-title":"Oncogene"},{"issue":"6","key":"pone.0340472.ref033","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/annonc\/mdg240","article-title":"Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites","volume":"14","author":"A Fedier","year":"2003","journal-title":"Ann Oncol"},{"issue":"5","key":"pone.0340472.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020311","article-title":"Targeting the DNA double strand break repair machinery in prostate cancer","volume":"6","author":"FS Shaheen","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"pone.0340472.ref035","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"SE Golding","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"key":"pone.0340472.ref036","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2005.09.029","article-title":"Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated","volume":"71","author":"IG Cowell","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"pone.0340472.ref037","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.dnarep.2012.08.006","article-title":"Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells","volume":"11","author":"Z Korwek","year":"2012","journal-title":"DNA Repair (Amst)"},{"issue":"11","key":"pone.0340472.ref038","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous Targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells","volume":"23","author":"K Sullivan-Reed","year":"2018","journal-title":"Cell Rep"},{"key":"pone.0340472.ref039","article-title":"ATM and ATR signaling at a glance","author":"P Awasthi","year":"2015","journal-title":"J Cell Sci"},{"issue":"4","key":"pone.0340472.ref040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4248\/IJOS11064","article-title":"DNA repair and synthetic lethality","volume":"3","author":"G-S Guo","year":"2011","journal-title":"Int J Oral Sci"},{"key":"pone.0340472.ref041","doi-asserted-by":"crossref","first-page":"123079","DOI":"10.1016\/j.biomaterials.2024.123079","article-title":"Non-viral, high throughput genetic engineering of primary immune cells using nanostraw-mediated transfection","volume":"317","author":"ARK Kumar","year":"2025","journal-title":"Biomaterials"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:29:37Z","timestamp":1768933777000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340472"}},"subtitle":[],"editor":[{"given":"Vino","family":"Cheriyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340472","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}